Turnstone Biologics

Turnstone Biologics is a private immuno-oncology company with the mission to deliver breakthrough viral immunotherapies to improve survival rates for cancer patients. Turnstone's platform and intellectual property are based on discoveries by leading researchers in the field of oncolytic virus immunotherapy, including Dr. John Bell, Dr. Brian Lichty, and Dr. David Stojdl. Four Canadian academic institutions, together with the Fight Against Cancer Innovation Trust (FACIT), have propelled Turnstone to a leadership position in advancing its immunotherapy product into Phase I/II clinical development studies for late-stage cancer patients. The company is developing a groundbreaking engineered viral immunotherapy using drugs designed to combat tumors at multiple intervention points, addressing the complexity of cancer by simultaneously generating targeted immune responses and modulating the tumor microenvironment.